z-logo
Premium
Association of lower eosinophil‐related T helper 2 (Th2) cytokines with coronary artery lesions in Kawasaki disease
Author(s) -
Kuo HoChang,
Wang ChihLu,
Liang Chi Di,
Yu HongRen,
Huang ChienFu,
Wang Lin,
Hwang KaoPin,
Yang Kuender D.
Publication year - 2009
Publication title -
pediatric allergy and immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.269
H-Index - 89
eISSN - 1399-3038
pISSN - 0905-6157
DOI - 10.1111/j.1399-3038.2008.00779.x
Subject(s) - medicine , eosinophilia , eotaxin , eosinophil cationic protein , eosinophil , kawasaki disease , immunology , interleukin 5 , vasculitis , interleukin , gastroenterology , cytokine , artery , disease , asthma
Kawasaki disease (KD) is a systemic febrile vasculitis particular coronary artery involvement. Eosinophilia has been found in our and other studies in KD. This study further investigates whether eosinophil‐related T helper 2 (Th2) cytokines or the activation marker (eosinophil cationic protein – ECP) is involved in KD with coronary artery lesions (CAL). A total of 95 KD patients were enrolled for this study. Plasma samples were subjected to the measurement of interleukin (IL)‐4, IL‐5, and eotaxin by Luminex‐Bedalyte multiplex beadmates system and to the measurement of ECP by fluoroimmunoassay. Patients with KD had higher eosinophils than controls. Eosinophil‐related mediators: IL‐4, IL‐5, eotaxin, and ECP levels were also higher in KD patients than controls before intravenous immunoglobulin (IVIG) treatment. After IVIG treatment, ECP decreased but IL‐4, IL‐5, and eotaxin increased significantly. The higher the IL‐5 and eosinophil levels after IVIG treatment, the lower rate of CAL was found. Changes of eosinophils after IVIG treatment were positively correlated to changes of IL‐5 levels but not ECP levels. An increase of eosinophils and IL‐5, but not ECP levels after IVIG treatment, was inversely correlated with CAL formation in KD.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here